Media ReleasesImmutep

View All Immutep News


Immutep announces First patient dosed in INSIGHT-004

Highlights

  • First patient received first dose in INSIGHT-004, a phase I clinical trial
  • Evaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indications
  • Patient recruitment for the trial is ongoing in Germany, with first data expected in 2019
For further information please download PDF attached: Download this document